Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart

被引：0
|
作者：
Pieber, T. R. [1 ]
Basu, A. [2 ]
Hansen, A. K. [3 ]
Sach-Friedl, S. [1 ]
Thomsen, K. M. D. [3 ]
Basu, R. [2 ]
Haahr, H. [3 ]
机构：
[1] Med Univ Graz, Graz, Austria
[2] Mayo Clin, Rochester, MN USA
[3] Novo Nordisk, Soborg, Denmark
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
690
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [1] Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart
    Basu, Ananda
    Pieber, Thomas R.
    Hansen, Ann K.
    Sach-Friedl, Stefanie
    Erichsen, Lars
    Basu, Rita
    Haahr, Hanne
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1615 - 1622
  • [2] EVALUATION OF EARLY POSTPRANDIAL SUPPRESSION OF ENDOGENOUS GLUCOSE PRODUCTION WITH FASTER ASPART VERSUS INSULIN ASPART
    Pieber, T.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A33 - A33
  • [3] Evaluation of Early Postprandial Suppression of Endogenous Glucose Production with Faster Aspart vs. Insulin Aspart
    Basu, Ananda
    Pieber, Thomas R.
    Hansen, Ann Kathrine
    Sach-Friedl, Stefanie
    Thomsen, Karen Margrete D.
    Basu, Rita
    Haahr, Hanne
    [J]. DIABETES, 2017, 66 : A248 - A248
  • [4] Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart
    Pieber, Thomas R.
    Svehlikova, Eva
    Brunner, Martina
    Halberg, Inge B.
    Thomsen, Karen Margrete Due
    Haahr, Hanne
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2068 - 2075
  • [5] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Marc Evans
    Mathew Wilkinson
    Angeliki Giannpolou
    [J]. Diabetes Therapy, 2019, 10 : 1793 - 1800
  • [6] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Evans, Marc
    Wilkinson, Mathew
    Giannpolou, Angeliki
    [J]. DIABETES THERAPY, 2019, 10 (05) : 1793 - 1800
  • [7] A trial of fast-acting aspart insulin (FIASP) in insulin pumps
    Khan, A. K.
    Weston, P. W. Philip
    Brake, J. B.
    Lamen, L. L.
    Ndebu, J. N.
    Ord, C. O.
    [J]. DIABETIC MEDICINE, 2023, 40
  • [8] Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes
    Bowering, K.
    Harvey, J.
    Kolaczynski, J. W.
    Snyder, J. W.
    Bode, B. W.
    [J]. DIABETIC MEDICINE, 2019, 36 (06) : 771 - 775
  • [9] Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart
    Shiramoto, Masanari
    Nishida, Tomoyuki
    Hansen, Ann Kathrine
    Haahr, Hanne
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 303 - 310
  • [10] Cost impact analysis of mealtime fast-acting insulin aspart compared with insulin aspart in adults with Type 1 diabetes in the UK
    Pollock, R. F.
    Parekh, W.
    Watcham, S.
    Hallen, N.
    [J]. DIABETIC MEDICINE, 2019, 36 : 166 - 166
12345